Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신수진 | - |
dc.date.accessioned | 2017-09-15T01:45:12Z | - |
dc.date.available | 2017-09-15T01:45:12Z | - |
dc.date.issued | 2015-11 | - |
dc.identifier.citation | ONCOLOGIST, v. 20, NO 11, Page. 1253-1260 | en_US |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.issn | 1549-490X | - |
dc.identifier.uri | http://theoncologist.alphamedpress.org/content/20/11/1253 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/29187 | - |
dc.description.abstract | Background. Vascular endothelial growth factor pathway (VEGF)tyrosine kinase inhibitors (TKIs) are used as the first-line treatment for patients with metastatic clear cell renal cell carcinoma (mCCRCC). Recently, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) blockade emerged as promising therapy for renal cell carcinoma. However, the expression pattern and prognostic implication of programmed death-ligands (PD-Ls) in mCCRCC patients receiving VEGF-TKI remain unclear. Patients and Methods. PD-L1 and PD-L2 expression in tumor cells and the quantities of PD-1+ tumor-infiltrating lymphocytes were immunohistochemically evaluated in 91 mCCRCC patients treated with VEGF-TKI, and their associations with VEGF-TKI responsiveness and clinical outcome were analyzed. Results. PD-L1 immunopositivity was observed in 17.6% and significantly associated with a high International Society of Urological Pathology grade (p = .031) and sarcomatoid features (p = .014). PD-L2 immunopositivity was observed in 39.6% and was not associated with any of the assessed clinicopathological variables. PD-L1-positive cases showed poor VEGF-TKI responsiveness (p = .012) compared with PD-L1-negative cases. In univariate survival analysis, PD-L1 immunopositivity was significantly associated with shorter overall survival (OS) (p = .037) and progression-free survival (PFS) (p = .043). Multivariate survival analysis revealed that PD-L1 expression was independently associated with poor OS (p = .038) and PFS (p = .013) in addition totumor necrosis (p = .006; p = .029, respectively) and Memorial Sloan Kettering Cancer Center score (p = .018; p = .032, respectively). PD-L2 expression was neither associated with VEGF-TKI responsiveness nor patients' outcome. Conclusion. PD-L1 expression was significantly related to lack of VEGF-TKI responsiveness and independently associated with shorter survival in mCCRCC patients after VEGF-TKI treatment. PD-L1 may have a predictive and prognostic value for determining the value of VEGF-TKI treatment in patients with mCCRCC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ALPHAMED PRESS | en_US |
dc.subject | Metastatic clear cell renal cell carcinoma | en_US |
dc.subject | Programmed death ligand-2 | en_US |
dc.subject | Programmed death ligand-1 | en_US |
dc.subject | Vascular endothelial growth factor pathway-tyrosine kinase inhibitor | en_US |
dc.subject | Responsiveness | en_US |
dc.subject | Prognosis | en_US |
dc.title | The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma | en_US |
dc.type | Article | en_US |
dc.relation.no | 11 | - |
dc.relation.volume | 20 | - |
dc.identifier.doi | 10.1634/theoncologist.2015-0151 | - |
dc.relation.page | 1253-1260 | - |
dc.relation.journal | ONCOLOGIST | - |
dc.contributor.googleauthor | Shin, Su-Jin | - |
dc.contributor.googleauthor | Jeon, Yoon Kyung | - |
dc.contributor.googleauthor | Cho, Yong Mee | - |
dc.contributor.googleauthor | Lee, Jae-Lyun | - |
dc.contributor.googleauthor | Chung, Doo Hyun | - |
dc.contributor.googleauthor | Park, Ji Young | - |
dc.contributor.googleauthor | Go, Heounjeong | - |
dc.relation.code | 2015013018 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | charm | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.